

c.a.r.u.s. IT platform ViSoR: The turbo for drug development at the BIOTECHNICA 2008

Norderstedt/Hannover October 7th, 2008. c.a.r.u.s. delivers a first insight into its IT platform ViSoR, which provides a significant step in the direction of an accelerated development of pharmaceuticals.

As a “digital workplace”, ViSoR (Virtual Screening optimizing the Reality) supports the identification of potential targets in drug research. For the first time ever in-vitro and in-silico-methods can be integrated in one system. All occurring data during the target-search is centralized in the digital workplace. ViSoR enables the combination and revelation of relevant scientific contexts and therefore delivers an advantage of knowledge. The future platform will be a standardized application, replacing several specific applications in the laboratories and providing a productive dialogue between research companies and institutions. “The scientific exchange within networks and institutions is ensured and will change the scientific work fundamentally as ViSoR maps the entire research workflow”, explains Dr. Matthias Rath, executive of c.a.r.u.s. HMS GmbH.

The knowledge exchange and documentation of the used and generated data increase the chance to identify targets and delivers results for the pharmaceutical design in a time- and cost-efficient way. The platform technology ViSoR is based on the combination of different research methods. It supports for example the wet-chemical and IT-based target-search.

The company, based in Norderstedt, has been researching and developing the software since the end of 2007 in cooperation with the European Screening Port and the Department for Bioinformatics of the University of Hamburg. The project is supported by the funding program “Betriebliche Innovationen – Spitzeninnovationen” with 1.7 million euro of the federal ministry Schleswig-Holstein for Science, Economy and Transportation.

The development of new pharmaceuticals is a tedious and cost-intensive process. The market-ready development of a single pharmaceutical, until it can be offered in a pharmacy, costs the analysts of The Boston Consulting Group about 550 million Euro. In the light of these cost- and time-ranges the decrease of the development time with the help of the IT platform ViSoR presents a significant added value to the pharmaceutical research enterprises and institutions. The final product of the



ViSoR development will be a commercially marketable IT platform supporting the pharmaceutical Drug Discovery Process.

First functionalities are presented at the halftime of the project, a first product version will be completed at the end of 2009.

c.a.r.u.s. Healthcare

c.a.r.u.s. can reflect upon many years of experience in the area of Life Sciences. Based on the HealthCare business new areas in pharmaceutical research resulted.

For years c.a.r.u.s. has supported and advised the deployment of High Performance Solutions and the resulting challenges in IT. In addition to the development of new and the adaptation of existing software in companies, we provide our experience and competencies in the high end infrastructure area. In cooperation with IT-systems from IBM, optimized especially for these purposes, we realize efficient grid-systems. c.a.r.u.s. has been active for several years in the area of Cluster and Grid-Computing. Over the last years several projects were realized and extensive know-how was established. Our strategy for the future is the expansion of these competencies, especially in the area of Grid-Computing.

Contact:

Ulrike Hampe

Marketing & Communications
c.a.r.u.s. Information Technology AG
Bornbarch 9, 22848 Norderstedt
fon +49. (0)40. 514 35-2419
fax +49. (0)40. 514 35-11 11
Ulrike.Hampe@carus-it.com
www.carus-it.com



ZUKUNFTSprogramm
Schleswig-Holstein
Investition in Ihre Zukunft